Literature DB >> 11001322

Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis.

P Sinha1, S Kohl, J Fischer, G Hütter, M Kern, E Köttgen, M Dietel, H Lage, M Schnölzer, D Schadendorf.   

Abstract

A model system for studying chemoresistance in human melanoma cells (MeWo) has been established utilizing the four commonly used cytotoxic drugs vindesine, cisplatin, fotemustine and etoposide to yield stable drug-resistant sublines. We analyzed phenotypical differences between MeWo cells and their chemoresistant counterparts using two-dimensional electrophoresis. Proteins that were overexpressed in chemoresistant cell lines were purified and identified using matrix assisted laser desorption/ionization-time of flight - mass spectrometry (MALDI-TOF-MS) and microsequencing. Here we show that four proteins, namely the translationally controlled tumor protein, the human elongation factor 1-delta, tetratricopeptide repeat protein and the isoform 14-3-3-gamma of the 14-3-3-family are overexpressed in chemoresistant melanoma cell lines. The significance of these findings is now being verified using transfection experiments with the aim of developing more effective chemotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001322     DOI: 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  29 in total

1.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

2.  A novel inhibitor of Rho GDP-dissociation inhibitor α improves the therapeutic efficacy of paclitaxel in Lewis lung carcinoma.

Authors:  Xing Chen Peng; Xu Xia Chen; Y U Zhang; Hai Jun Wang; You Feng
Journal:  Biomed Rep       Date:  2015-05-27

3.  A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.

Authors:  Xingchen Peng; Fengming Gong; Gang Xie; Yuwei Zhao; Minghai Tang; Luoting Yu; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2011-01-18       Impact factor: 3.396

Review 4.  14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Authors:  Christopher L Neal; Dihua Yu
Journal:  Expert Opin Ther Targets       Date:  2010-12       Impact factor: 6.902

Review 5.  Drug resistance mediated by AEG-1/MTDH/LYRIC.

Authors:  Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling.

Authors:  Mee-Jung Han; Huan Wang; Lynn A Beer; Hsin-Yao Tang; Meenhard Herlyn; David W Speicher
Journal:  Proteomics       Date:  2010-11-17       Impact factor: 3.984

7.  Molecular cloning, expression analysis and chromosome localization of the Tpt1 gene coding for the pig translationally controlled tumor protein (TCTP).

Authors:  Noemí Yubero; Gloria Esteso; Henry Cardona; Luis Morera; Juan J Garrido; Manuel Barbancho
Journal:  Mol Biol Rep       Date:  2008-11-05       Impact factor: 2.316

Review 8.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

9.  YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.

Authors:  Yan Xu; Mariateresa Fulciniti; Mehmet K Samur; Matthew Ho; Shuhui Deng; Lanting Liu; Kenneth Wen; Tengteng Yu; Zuzana Chyra; Sanika Dereibal; Li Zhang; Yao Yao; Chandraditya Chakraborty; Eugenio Morelli; Na Li; Michael A Lopez; Tommaso Perini; Shidai Mu; Gang An; Rafael Alonso; Giada Bianchi; Yu-Tzu Tai; Kenneth C Anderson; Lugui Qiu; Nikhil C Munshi
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

10.  Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model.

Authors:  Jung Eun Kim; Kyung Hee Koo; Yeul Hong Kim; Jeongwon Sohn; Yun Gyu Park
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.